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The angiotensinogen M235T polymorphism in humans is linked to
differential expression of the human angiotensinogen gene (AGT)
gene and hypertension, but the homeostatic responses resulting
from this polymorphism are not known. We therefore investigated
how mice respond to five genetically determined levels of mouse
angiotensinogen gene (Agt) expression covering the range asso-
ciated with the M235T variants. By using high-throughput molec-
ular phenotyping, tissue RNAs were assayed for expression of 10
genes important in hypertension. Significant positive and negative
responses occurred in both sexes as Agt expression increased
twofold, including a three-fold increase in aldosterone synthase
expression in adrenal gland, and a two-fold decrease in renin
expression in kidney. In males, cardiac expression of the precursor
of atrial natriuretic peptide B and of adrenomedullin also increased
approximately twofold. The relative expression of all genes stud-
ied except Agt differed significantly in the two sexes, and several
unexpected relationships were encountered. A highly significant
correlation between renal expression of the angiotensin type 1a
receptor and kallikrein, independent of Agt genotype, is present in
females (P < 0.0001) but not males (P  0.4). The correlation
between blood pressure (BP) and liver Agt expression within the
five Agt genotypes is significant in females (P  0.0005) but not in
males (P  0.2), whereas correlation of BP with differences be-
tween the genotypes is less in females (P  0.06) than in males (P 
0.001). The marked gender differences in gene expression in
wild-type mice and the changes induced by moderate alterations
in Agt expression and BP emphasize the need to look for similar
differences in humans.
Essential hypertension is a deleterious condition with a mul-tifactorial etiology that includes both genetic and environ-
mental determinants. However, despite decades of intense re-
search into the physiological mechanisms that regulate blood
pressure (BP), the primary genetic determinants of essential
hypertension remain elusive. A substantial source of the diffi-
culties associated with attempts to understand the regulation of
BP is the existence of sophisticated homeostatic systems that
permit desirable physiological changes in biological variables in
vivo but prevent the changes from extending into pathological
ranges. These homeostatic changes, combined with environmen-
tal effects and the difficulties of obtaining measurements of BP
sufficiently precise to detect small differences, make dissection
of the hypertensive phenotype difficult.
Because humans are genetically very heterogenous, polymorphic
forms of genes are common. Consequently, among the polymorphic
forms, it is reasonable to expect that different alleles will exist that
dictate expression at different intrinsic levels. Such genetic varia-
tions may cause BP changes if the recruiting homeostatic adjust-
ments are incomplete. The M235 and T235 alleles of the human
angiotensinogen gene (AGT), described by Jeunemaitre et al. (1),
affect BP. Thus, it is important to understand in detail the homeo-
static adjustments that occur in response to this type of genetic
alteration and to identify genes that are called into action during
homeostasis. The responding genes themselves then become can-
didates for having effects on BP. Obviously, however, a precise
analysis of this type is difficult in humans because of their heter-
ogeneous genetic background.
For these reasons, we have recently been carrying out exper-
iments in mice with the aim of identifying genes whose quanti-
tative expression affects BP or induces homeostatic compensa-
tions. To do this, we first use targeted gene disruption and gene
duplication to generate mice having different numbers of the
target gene (2) and then use this ‘‘gene titration’’ series of mice
to uncover changes that directly influence BP and those that
represent homeostatic compensations. Our first application of
this strategy has centered on the renin-angiotensin system
(RAS), which plays a central role in salt and water homeostasis
and the maintenance of vascular tone. Angiotensinogen (AGT)
is the sole source of angiotensin II (Ang II), the most active
peptide of the RAS, which is produced from AGT by the serial
actions of renin and the angiotensin-converting enzyme. Of all
of the components in the RAS, AGT is the one most definitively
identified as genetically important in the causation of essential
hypertension in humans (1, 3) and in animals (4–6).
The mice we have studied here carry one, two, three, or four
functional copies of the murine wild-type mouse angiotensinogen
gene (Agt) at its normal chromosomal location (2, 6). Plasma AGT
levels increase progressively from 35% in the one-copy mice to
145% of normal in the four-copy animals, and their BPs show
significant and almost linear increases of 8 mmHg (1 mmHg 
133 Pa) per gene copy, even though their normal homeostatic
systems are intact. Thus, the ranges of AGT alteration and BP in the
mice include those observed in humans with variant AGT alleles.
We have reported on the nature of the homeostatic compensations
that occur in the one-copy mice (7). In the present article we extend
this work to include increases as well as decreases in the expression
of AGT, and we move from studying expression at the level of
proteins and peptides to the study of expression at the level of
mRNA. We do so for several reasons. First, the quantitation of the
proteins and peptides requires a unique method for each compo-
nent. Second, distinguishing between related components is often
difficult. Third, sensitivities and precision are not always adequate.
Fourth, high-throughput determinations are only available for some
components. These difficulties can all be circumvented in experi-
mental animals when expression is studied at the mRNA level and
quantitative reverse transcription (RT)-PCR is used in conjunction
with automated RNA preparation. Our application of this molec-
ular phenotyping system to animals in the Agt gene titration series
illustrates its power for recognizing subtle phenotypic changes in
animals with minimal genetic differences and reveals several un-
expected findings.
Abbreviations: RAS, renin-angiotensin system; Ang II, angiotensin II; BP, blood pressure;
AGT, angiotensinogen; RT, reverse transcription.
*To whom reprint requests should be addressed. E-mail: hskim@med.unc.edu.
†Present address: The Jackson Laboratory, Bar Harbor, ME 04609.
The publication costs of this article were defrayed in part by page charge payment. This
article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C.
§1734 solely to indicate this fact.
4602–4607  PNAS  April 2, 2002  vol. 99  no. 7 www.pnas.orgcgidoi10.1073pnas.072083799
Experimental Procedures
Animals. The experimental mice used in this investigation have
different numbers of the functional Agt gene (6). Their geno-
types are Agt 01 (with one wild-type copy of the gene), Agt 02
(with a tandemly duplicated copy of the gene), Agt 11 (wild type
with two singleton copies of the gene), Agt12 (one wild-type and
one duplicated copy), and Agt 22 (two duplicated copies). The
original gene targeting was in embryonic stem cells derived from
strain 129 Ola. All mice used in this work were, however, from
a seventh-generation back cross to strain C57BL6J (B6). The
mice were fed regular chow and were handled following the
National Institutes of Health guidelines for the care and use of
experimental animals. Most were 3–4 months in age.
High-Throughput Tissue Processing and RNA Isolation. Livers, kid-
neys, adrenal glands, and whole hearts were stored with 5 (volwt)
volumes of ‘‘RNA later’’ solution (Ambion, Austin, TX). Small
pieces of tissue (50–100 mg) were added to 2-ml special tubes
containing 1 ml of lysis buffer made by diluting 2 RNA lysis buffer
(PE Biosystems, Foster City, CA) with Ca2- and Mg2-free PBS.
The tissues were macerated with a 14-inch cylindrical bead at
speed 4 for 30 sec in a Fast Prep 120 mixer (QBIOgene, Vista, CA).
Tissue homogenates were transferred into Eppendorf tubes, heated
to 50°C for 2 min, then centrifuged at 25°C for 1 min at 10,000 
g to remove tissue debris. Tissue solutions were stored at 20°C for
up to 16 h before use for RNA isolations in an RNA purification
tray, using the ABI Prism 6700 automated nucleic acid workstation
(PE Biosystems) and following the manufacturer’s protocol. Total
RNA samples were stored at 20°C.
Primers and Probes. The nucleotide sequences of the PCR primers
and their f luorogenic probes for the target genes (provided as
supporting information, which is published on the PNAS web
site, www.pnas.org) were designed by using the computer pro-
gram PRIMER EXPRESS (PE Biosystems). Each fluorescent probe
has a reporter dye (FAM for the target RNA and TET for the
-actin control) covalently attached at its 5 end and a quencher
dye (TAMRA) attached at its 3 end. Before use, the probes
were purified in the PolyPak II cartridge (Glen Research,
Sterling, VA) following the manufacturer’s instructions.
RT-PCR Amplifications. Real-time RT-PCR amplifications (8) were
performed in a 96-well plate in the ABI Prism 7700 sequence
detector (PE Biosystems) in a total volume of 30 l, which
included 10 l of RNA sample from the ABI Prism 6700 plus 20
l of a reaction mixture made with minor modifications of the
manufacturer’s instructions. Each RT-PCR amplification was
performed in duplicate: 30 min at 48°C for the RT reaction, then
10 min at 94°C, followed by a total of 40 temperature cycles (15
sec at 94°C and 1 min at 60°C). During the amplification, the
fluorescence of FAM (or TET), TAMRA, and ROX (a passive
reference dye) was measured by the 7700 sequence detector in
each well of the 96-well plate. The numbers of copies of the PCR
template in the starting sample were calculated by using the
SEQUENCE DETECTOR SOFTWARE incorporated in the ABI Prism
7700 Sequence Detector System.
Relative Quantification of Gene Expression. Standard plasmids con-
taining a DNA fragment for each of the genes of interest were
used as external controls, and amplification of the -actin gene
was used as an endogenous control. Sense RNAs were synthe-
sized from the standard plasmids by the manufacturer’s proto-
cols, using a MAXIscript transcription kit (Ambion). The con-
centrations of purified sense RNAs were determined as
micrograms per optical density unit, and serial dilutions of the
sense RNA, using bacterial tRNA as a carrier, were used to
generate standard curves. When quantification was relative to an
endogenous control, standard curves were prepared for both the
target and the endogenous control. For each experimental
sample, the amounts of the target and of the endogenous control
were determined from the appropriate standard curves. We
assume that -actin mRNA is present in all tested and control
samples of tissue RNA at a constant proportion and normalize
the amount of total RNA in our test samples by comparing their
-actin fluorescent signal after PCR with that from mouse
embryonic stem cell RNA freed from DNA by DNase treatment.
Statistics. Unless otherwise indicated, ANOVA and multivariate
regression analyses were used for statistical evaluations with JMP
software (SAS Institute, Cary, NC).
Results
Expression of 10 Genes Relevant to the Control of BP. The levels of
Agt mRNA in the livers of mice (five females and five males) with
each of five different Agt genotypes are presented in Fig. 1 as
percentages of wild type. Their genotypes and expression are as
follows: Agt 01, 65  3% (01 mice have one copy of the
wild-type Agt gene and one inactivated copy); Agt 02, 84  4%
(02 mice have one tandemly duplicated pair of Agt genes); Agt
11, 100  3% (11 mice have two copies of the wild-type gene);
Agt 21, 112  3% (21 mice have one duplicated pair and one
wild-type gene); Agt 22, 125  6% (22 mice have two
duplicated pairs). There were no differences in the liver Agt
mRNA levels in males and females (P  0.20, Table 1), thus the
data from both sexes were combined in Fig. 1. The mRNA levels
in the Agt 02 mice were less than those in the Agt 11mice,
although both have two copies of the gene, indicating that the
two genes in the tandemly duplicated Agt gene pair are expressed
at approximately 80% of two wild-type genes. Together, the
gradation in the liver Agt expression in mice of the five Agt
genotypes is gently progressive. Despite this gentle progression
(which averages only 15% among each of the genotypes), the
molecular phenotyping procedure allows the five genotypes to be
distinguished from each other (P  0.05) solely on the basis of
Agt mRNA measurements.
We next assessed the effects of the genetically induced changes
in Agt expression on the expression of nine additional genes: renin
Fig. 1. AGT mRNA levels in mice with different Agt genotypes. The levels of
mRNAs in the livers are presented as percentages of wild type (11). Five males
and five females were used for each genotype. The bars show means  SEM.











(Ren), Ang II receptor 1a (Atr1a), kallikrein 1 (Klk1), and endo-
thelial nitric oxide synthase (Nos3) in the kidney; angiotensin-
converting enzyme (Ace) in the lung; aldosterone synthase
(Cyp11b2, hereafter referred to AS) in the adrenal gland; and the
genes coding for the precursors of atrial natriuretic peptides A and
B (Nppa and Nppb) and for adrenomedullin (Adm) in the heart.
Data were first analyzed by ANOVA with Agt genotype and gender
as two variables (Table 1). With the exception of Ace mRNA levels
in the lung, strong Agt genotype-dependent differences were found
in the expression of the genes in the RAS pathway. Thus, a gradual
decrease in the mRNA levels of Ren as Agt expression increases
twofold in the five genotypes resulted in a two-fold difference
between the Agt22 and Agt01 mice (P  0.0001). This decrease
of Ren expression is the major homeostatic response that we
observe consequent to the increase in BP caused by the genetic
increase in AGT. In contrast, in response to the increased AGT,
mRNA levels of AS progressively increase over a three-fold range
in animals of the five genotypes. Activation of aldosterone synthesis
by Ang II (9) is well known, and we presume that this increase of
AS mRNA indicates the direct effects on AS expression of an
increase in intra-adrenal Ang II. Our data indicate that any negative
feedback between the elevated BP and aldosterone synthesis, if it
exists, is ineffective. We observe modest but significant genotype-
and gender-dependent differences in Atr1a expression, although
there is no clear trend in these differences. In contrast to the genes
in the RAS, expression of the Klk1 and Nos3 genes in the kidney,
and of Nppa and Adm in the heart, do not differ significantly among
the five genotypes. There is, however, a significant increase in the
cardiac expression of Nppb in 12 and 22 males compared with
males in the other groups (P  0.001, Tukey–Kramer). This change
was not observed in females (see below).
Gender-Specific Effects. As illustrated in Table 1, the expressions of
8 of 10 of the genes we studied, with the exception of Agt and Ace,
are significantly affected by gender, and in some cases in opposite
directions, with probabilities ranging from 0.0001 for Ren, AS,
Nppa, and Nos3, to 0.02 for Adm, and with malefemale ratios
ranging from 2.05 for Ren to 0.42 for cardiac Nppa. The expression
of Agt and Ace were not affected by gender. Furthermore, the
effects of Agt genotype on the expression of the eight gender-
sensitive genes were frequently different in the two sexes. For
example, the cardiac expressions of Nppb and Adm in females were
not influenced by Agt genotype (P  0.45 and 0.7, respectively) but
were highly influenced by Agt genotype in males (P  0.0001 and
0.002). Because of these strong gender effects, the data for the
male and female mice are presented and analyzed separately.
The left lower half of Fig. 2 summarizes the data from the
females in the form of a scatterplot matrix of the individual
measurements for the 25 females studied (5 per genotype) for
each of the 10 mRNAs assayed with a 95% bivariate normal
density ellipse superimposed on each scatterplot. (The BP
measurements included in the figure are discussed below.) To
simplify the figure, individual data points are shown only when
the corresponding correlation is significant. The right upper half
of the figure tabulates the probability (P) that the observed
correlations occur by chance based on analysis of the Pearson
product moment correlations. Again, for simplicity, only signif-
icant probabilities are shown. The degree of asymmetry of the
95% bivariate ellipses provides visual representations of the
significance of each correlation. For example, the ellipse in
square A2 is markedly asymmetric, indicating a strong inverse
correlation between kidney Ren mRNA and liver Agt expression;
square B1 shows the corresponding P value, 0.0005. One other
strong direct correlation is detected in the mRNA data from
females, namely that between liver Agt expression and adrenal
gland AS mRNA (squares A5 and E1, P  0.0006).
Pairwise correlations outside the primary experimental design
(which was to investigate how genetic variations in Agt expression
affect other molecular parameters) can reveal previously unex-
pected relationships, but estimating their significance requires
caution. A secondary correlation between the expression of Ren
in the kidney and of AS in the adrenal gland (Fig. 2, squares B5
and E2, P  0.004) is the result of the corresponding two
components each being correlated with Agt mRNA expression in
the primary analysis as described in the preceding paragraph.
Assessing the significance of other secondary correlations must
take into account the number of pairwise comparisons tested. A
total of 28 comparisons involving the expression of pairs of genes
other than those with Agt are included in the tabulation. If
Bonferroni’s correction is applied to these comparisons, a P of
Table 1. mRNA levels for 10 genes vs. Agt genotype and gender
Gene Gender
Agt genotype P (ANOVA)
01 02 11 12 22 Genotype Gender Interaction
Agt F 94  6 122  10 154  9 170  9 192  17
0.0001 0.2 0.8
M 94  5 119  6 141  5 161  5 177  10
Ren F 89  11 72  10 55  5 58  8 45  3
0.0001 0.0001 0.4
M 47  7 30  3 30  2 20  3 23  3
Ace F 172  25 151  18 153  22 143  18 150  15
0.8 0.5 0.9
M 161  11 156  16 161  11 148  15 180  19
Atr1a F 12.7  0.3 12.2  0.5 10.9  0.4 12.9  1.0 14.5  8.9
0.001 0.002 0.007
M 9.9  0.6 11.0  0.7 10.4  0.5 12.2  0.6 12.8  0.6
AS F 397  52 704  89 691  80 992  76 1149  82
0.0001 0.0001 0.02
M 594  16 941  56 957  94 1249  76 1885  176
Klk1 F 6.5  0.1 7.5  0.5 6.3  0.3 7.6  0.7 8.3  0.6
0.09 0.0003 0.06
M 6.1  0.6 6.2  0.2 6.5  0.3 5.6  0.1 6.4  0.4
Nos3 F 8.9  0.4 8.7  0.5 10.2  0.4 9.0  0.4 9.1  0.9
0.2 0.0001 0.06
M 8.1  0.9 7.9  0.8 6.6  0.4 5.2  0.6 6.7  0.8
Nppa F 1304  70 915  89 1341  144 1024  45 1232  90
0.09 0.0001 0.01
M 413  69 495  98 503  25 539  56 466  41
Nppb F 101  6 88  12 106  13 89  4 87  12
0.0001 0.9 0.0001
M 58  8 50  4 67  3 148  19 141  18
Adm F 68  8 66  9 82  10 74  9 73  9
0.04 0.02 0.1
M 42  7 53  8 54  3 78  7 76  6
Values are pgg of total RNA  SEM; n  5 for each genotype and gender.
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0.002 (0.0528) would conservatively indicate a significant
correlation. One pairwise correlation reaches well beyond this
level—that between kidney expression of Atr1a mRNA and
kidney expression of Klk1 (squares D6 and F4, P  0.0001)–
although neither is significantly influenced by changes in Agt
expression (squares A4 and A6).
Fig. 3 presents the equivalent comparisons for male mice. They
are considerably more complicated. The primary correlations with
Agt expression seen in females also occur in males—kidney Ren
expression (squares A2 and B1, P  0.003) and adrenal gland AS
expression (squares A5 and E1, P  0.0001). But in male mice, there
are two other strong primary correlations: liver Agt expression with
cardiac Nppb expression (squares A9 and I1, P  0.0001) and with
cardiac Adm (squares A10 and J1, P  0.0004). The secondary
correlations between these primaries all have P  0.01, except for
kidney Ren with cardiac Adm and Nppb. Two weaker primary
correlations are seen between liver Agt and kidney Atr1a (squares
A4 and D1, P  0.02) and between liver Agt and kidney Nos3
(squares A7 and G1, P  0.01).
Our overall conclusion from these comparisons is that genetic
changes in Agt gene expression markedly affect kidney renin and
adrenal gland aldosterone synthase expression in both females
and males. In females, but not in males, the expression of kidney
Atr1a and Klk1 is strongly correlated with the other but not with
Agt expression. In males, but not in females, changes in Agt
expression are associated with marked changes in the cardiac
expression of Nppb and Adm, and with less marked changes in
kidney Atr1a and Nos3.
BP and Gene Expression. To obtain an overview of the relevance
of the molecular phenotyping data to increases in BP and
hypertension, we measured the tail-cuff BP of the mice with 2,
3, or 4 copies of Agt gene. Row 11 in Fig. 2 presents the relevant
data for the 15 females. In agreement with previous reports (1,
6), we find that BP is positively correlated with variation in Agt
expression (squares A11 and K1). However, the degree to which
Agt expression and BP are correlated (P  0.0001) is very
remarkable. One other correlation is clear in females, namely an
inverse relationship between BP and cardiac Adm expression
(squares J11 and K10, P  0.01). Adrenal AS expression in
females is not significantly correlated with BP (squares E11 and
K5), indicating a lack of negative feedback of BP on aldosterone
synthesis.
Row 11 in Fig. 3 presents comparable BP data for the 15 males
with 2, 3, or 4 copies of the Agt gene. As in females, the
correlation between liver Agt expression and BP is very strong
(squares A11 and K1, P  0.0003). However, unlike females,
cardiac Adm expression in males is not correlated with BP
(squares J11 and K10), although cardiac Nppb expression is
correlated with BP (squares I11 and K9, P  0.001). Adrenal
gland expression of AS is likewise correlated with BP in males
(squares E11 and K5, P  0.006), as is renal expression of the
Atr1a (squares D11 and K4, P  0.01).
Fig. 4 A and B presents the results of an analysis by ANOVA
of BP vs. Agt genotype in the males (A) and females (B), and the
plots of BP against the leverage of Agt expression nested within
the Agt genotypes in males (C) and in females (D). When the data
are averaged by Agt genotype, ANOVA shows that BPs in males
are significantly affected by their genotypes [P  0.0015, r2 
0.66 (Fig. 4A)] but this effect is borderline in females [P  0.06,
r2  0.37 (Fig. 4B)]. However, when the data are analyzed by
individual animals, as presented in Fig. 2, a highly significant
correlation is seen between Agt mRNA levels and BP in both
sexes (P  0.0003, r2  0.65 in males and P  0.0001, r2  0.85
in females). This remarkably strong correlation between BP and
liver Agt expression in the individual female mice is considerably
greater than that observed when the BP and Agt expression are
averaged by genotype. Yet in individual males, r2 for BP vs. liver
Agt expression is high (0.68), although not appreciably more so
Fig. 2. Comparisons of gene expression and BP in individual female mice. The
left lower half of the figure presents the data in the form of a bivariate
scatterplot matrix of the individual measurements and the corresponding
95% confidence ellipses. In those pairwise comparisons that have a significant
correlation, the dots in the squares represent individual values; the right
upper half of the figure tabulates the corresponding probabilities. In the
pairwise comparisons without a significant correlation, only the 95% confi-
dence ellipses are shown. More detailed versions of Figs. 2 and 3 are provided
as supporting information.
Fig. 3. Comparisons of gene expression and BP in individual male mice.











than the r2 for BP vs. Agt expression averaged for each Agt
genotype (0.66). These similarities and differences suggest that
in females some factor in addition to the Agt genotype affects Agt
expression andor BP.
To explore this possibility further, we used ANOVA to test
whether the BPs of individual animals were correlated with differ-
ences in liver expression of Agt within the Agt genotypes in addition
to their correlation with expression differences between the geno-
types. The results of this analysis are illustrated by leverage plots for
males (Fig. 4C) and females (Fig. 4D) of BP vs. Agt levels nested
within the genotypes. The data are compelling. The effects of Agt
expression within the genotype are highly significant in females
(P  0.0005) but not in males (P  0.20).
Taken together, our data demonstrate that the homeostatic
adjustments in the RAS and elsewhere in the body are not
sufficient to normalize the BPs caused by modest alterations in
Agt expression. Furthermore, the data show that, although Agt
levels, because of our genetic manipulations, primarily account
for BP differences in individual males, in individual females
other factors are so strong that the effects of the genetically
induced changes in the Agt gene expression are partially masked.
Discussion
Single nucleotide polymorphisms (SNPs) represent a substantial
portion of human genetic variation, and considerable effort is
being expended in attempts to correlate their occurrence with
the incidence of disease. A corollary of this endeavor is the need
to be able to determine in experimental animals whether subtle
genetic differences have any phenotypic consequences. Our
present study explores the use of ‘‘molecular phenotyping’’ by
automated quantitative RT-PCR on RNA isolated from liver,
heart, kidney, and adrenals of experimental animals to uncover
phenotypic effects caused by subtle differences in the expression
of the gene (Agt) coding for AGT. We selected this gene because
an SNP in its promoter has been reported to have a quantitative
effect on its expression (10), and because this polymorphism has
been implicated with the incidence of hypertension (11). Our
first tests established that the molecular phenotyping procedure
can detect Agt expression differences between animals of dif-
ferent genotypes of the order of 15%. Because the sensitivity of
the system can be adjusted readily by changing the concentra-
tions of reagents, the phenotyping procedure is not limited to
abundantly expressed genes or to larger organs. Accordingly, we
chose to examine the expression of 10 genes that are relevant to
the control of BP or to the homeostatic changes induced when
BP deviates from normal.
Our finding that expression of the Ren gene in the kidney
decreases systematically over an approximately two-fold range as
the levels of hepatic Agt gene expression increase over a com-
parable two-fold range confirms and extends our earlier com-
parisons between wild-type mice and mice with only one func-
tional copy of the Agt gene (7). These homeostatic changes in
renal Ren gene expression are the largest compensatory adjust-
ments that we have observed consequent to the genetically
determined differences in Agt expression.
This adjustment of renin production by the RAS is, however,
insufficient to normalize BP as demonstrated by the systematic
increase of BP as the expression of Agt is genetically increased.
Part of this insufficiency is probably the result of an approxi-
mately three-fold increase in the expression of the AS gene in the
adrenal glands as Agt expression increases twofold, which we find
in both sexes (P  0.001), presumably because of increased
intra-adrenal Ang II levels directly acting on the promoter of the
AS gene (12) coupled with the absence of effective negative
feedback regulation between BP and aldosterone synthesis. A
support of this interpretation is our preliminary observation that
the plasma levels of Ang II and of aldosterone are both increased
in the Agt 22 animals to about 1.4 times their levels in wild-type
animals. Human patients with glucocorticoid-remediable aldo-
steronism carry an additional chimeric gene that fuses the
regulatory sequences of steroid 11 hydroxylase to the coding
sequences of AS; these patients have 1.5 times plasma aldoste-
rone levels and are hypertensive (13, 14).
Gender-related differences in gene expressions are to be ex-
pected, but we were surprised at both the generality of their
occurrence and the magnitude of the differences. More than half of
the 10 genes studied showed significant differences between the two
sexes in either their mean expression in the wild-type animals or the
changes of the mean expression across the five Agt genotypes. The
degree of difference was also remarkable, ranging from more than
twofold higher in males (for cardiac expression of Nppa) to more
than twofold less in males (for kidney Ren). But of greater interest
in relation to developing an understanding of gender effects on BP
was the sometimes opposite responses of genes to the genetic
changes in Agt expression and BP in animals of the two sexes.
Changes in expression of the precursors of BNP and Adm illustrate
this situation. Plasma levels of BNP have recently been used in
humans as an indicator of cardiac hypertrophy (15), and an increase
in cardiac expression of ANP has long been associated in experi-
mental animals with cardiac hypertrophy. Both BNP and ANP have
antihypertrophic effects by means of their binding to the natriuretic
peptide receptor A (NPRA). Yet the cardiac expression of these
natriuretic peptides changed in relation to Agt expression only in
males. Similarly, we find that in male mice the cardiac expression
of the Adm gene, which codes for the BP-lowering peptide ad-
renomedullin, is markedly increased (P  0.0004) by increases in
Agt expression and BP, but in females there is no correlation
between these factors. The relevance of these observations to
clinically significant situations is indicated by noting that male mice
develop more severe cardiac hypertrophy than females when the
gene coding for NPRA (the active receptor for all three of
natriuretic peptides) is inactivated (16), and that a deletion poly-
morphism in the promoter of the human gene for NPRA has been
shown to be significantly associated with essential hypertension
Fig. 4. Comparison of correlation between BP and Agt expression. The data
in A (males) and B (females) are from an analysis by ANOVA of BPs and Agt
genotypes. C (males) and D (females) present leverage plots of BP against
hepatic Agt mRNA expression nested within the Agt genotypes. The Agt
genotypes in C and D are 11 (E), 12 (F), and 22 (■ ).
4606  www.pnas.orgcgidoi10.1073pnas.072083799 Kim et al.
andor cardiac hypertrophy in a recent Japanese study (17). The
marked gender-related differences that we observe in wild-type
mice and in response to modest increases in Agt expression and in
BP emphasize the need to look for similar differences in humans.
Two completely unexpected findings from our study were
detected because the molecular phenotyping procedure is suf-
ficiently sensitive for the expression of multiple genes to be
determined in several tissues from each individual animal; it is
not necessary to pool samples from individual mice. In addition,
the precision of the data is such that differences among indi-
vidual animals can be detected and measured well enough to
lead to meaningful conclusions. The first of these findings is that
seen in females between expression in the kidney of the Atr1a
and Klk1 genes (P  0.0001, squares D6 and F4 in Fig. 2). To
ascertain that this correlation is not a type 1 error, we tested for
the presence of this correlation in a completely independent set
of mice (our unpublished data from animals in which the
expression of Atr1a was genetically varied over a range from 100
to 130% of the wild-type levels). A strong correlation between
the renal Atr1a and Klk1 gene expressions was again observed in
the females (P  0.0014, n  17) but not in the males (P  0.8,
n  21). Thus, these data strongly suggest that the Atr1a and Klk1
genes share a female-restricted regulatory mechanism related to
their expression in the kidney. A computer search for regulatory
sequences in the 5 f lanking DNA of these two genes identified
the sequence GGTATATGACC approximately 400 bases up-
stream of the start of transcription of the mouse Klk1 gene (18),
and the sequence GGTTGGAACC approximately 70 bases
upstream of the start of transcription of the mouse Atr1a gene.
These sequences are similar to a consensus sequence, GGT-
CANNNTGACC, identified as an estrogen-responsive element
(19–21), which suggests a possible role of estrogen in the
expression of these two genes. However, preliminary tests (un-
published data) indicate that the expression levels of the two
genes are still correlated in ovarectomized females with or
without administration of exogenous estradiol.
The second finding is that the BPs of male mice are very
significantly altered when the number of Agt genes is varied from
2 through 4 (P  0.0015), but in females this effect is borderline
(P  0.064) and is obscured by a highly significant correlation
between BP and liver Agt expression (P  0.0005) that is
unrelated to Agt genotype. The direct relevance of this finding to
humans is made clear by noting that the genetic linkage between
hypertension and the 235T variant described by Jeunemaitre et
al. (1) was significant in male sib-pairs but not in female sib-pairs,
even though the 235T variant was found significantly more often
in female hypertensives than in control subjects. Indeed, in
discussing the absence of the genetic linkage in females, the
authors speculated that ‘‘AGT contributes to hypertensive risk
directly in males but indirectly in females, as another estrogen-
modulated factor may mediate the impact of the AGT-associated
predisposition.’’ A putative estrogen-responsive element se-
quence, GGTCAGAAGGCC, approximately 300 bases up-
stream of the promoter region of the human AGT gene (22), and
GGGTAAATGTGTAACCC, at the homologous region of the
mouse Agt gene (23), support a role of estrogen in regulating Agt
gene expression. Additionally, plasma AGT levels in humans are
clearly increased after estrogen treatment and during pregnancy
(24–26). However, our observed variation in Agt mRNA levels
is unlikely to be accounted for by the estrous cycle (3-day) of
female mice, because the BP measurements and the isolation of
tissue for RNA preparation were at different times. We conclude
that in female mice (and probably in humans) either hepatic Agt
gene expression is an important factor in determining BP or both
are coregulated. The correlation between these factors is so
strong in the female mice (Fig. 4D) that it suggests the possibility
that the level of hepatic Agt gene expression could be used to
predict BP. In male mice there are additional factors involved,
such as adrenal AS and cardiac Nppb expression.
In summary, we have demonstrated the statistical and exper-
imental power of molecular phenotyping animals individually by
using high-precision quantitative RT-PCR. When applied to
mice with genetically determined differences in expression of the
Agt gene, the resulting modest alterations in liver Agt expression
were positively correlated with adrenal expression of aldoste-
rone synthase and negatively correlated with renal renin expres-
sion. The analyses also revealed a surprising number of signif-
icant gender-related differences in the expression and regulation
of genes related to the control of BP and cardiac hypertrophy.
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